Prime Medicine won a legal battle with Beam Therapeutics on Wednesday. Prime shares jumped while Beam stock skidded.

An independent arbitration panel ruled that developing Prime Medicine’s experimental drug for Alpha-1 Antitrypsin Deficiency ...

In late June 2026, an arbitration tribunal ruled that Prime Medicine did not breach its 2019 collaboration agreement with ...

Prime Medicine, Inc. wins arbitration vs. Beam Therapeutics Inc., advancing PM647 for AATD. Read more on PRME and BEAM stocks ...

Prime Medicine Inc. PRME said it secured a favorable, binding arbitration ruling in its dispute with Beam Therapeutics Inc.

Prime Medicine said it had won an arbitration dispute against Beam Therapeutics, a clash that had pitted two well-backed gene ...

Beam Therapeutics (NASDAQ:BEAM) is set to give its latest quarterly earnings report on Tuesday, 2024-11-05. Here's what investors need to know before the announcement. Analysts estimate that Beam ...

Prime Medicine (PRME) stock jumps after an arbitration tribunal sides with the company in its dispute with Beam Therapeutics ...

On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified cell ...

Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease (SCD), an inherited blood disorder.

Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) at the 2025 Alpha-1 ...